Does TRASTUZUMAB DERUXTECAN Cause Interstitial lung disease? 130 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 130 reports of Interstitial lung disease have been filed in association with TRASTUZUMAB DERUXTECAN (Enhertu). This represents 4.8% of all adverse event reports for TRASTUZUMAB DERUXTECAN.
130
Reports of Interstitial lung disease with TRASTUZUMAB DERUXTECAN
4.8%
of all TRASTUZUMAB DERUXTECAN reports
46
Deaths
46
Hospitalizations
How Dangerous Is Interstitial lung disease From TRASTUZUMAB DERUXTECAN?
Of the 130 reports, 46 (35.4%) resulted in death, 46 (35.4%) required hospitalization, and 15 (11.5%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for TRASTUZUMAB DERUXTECAN.
What Other Side Effects Does TRASTUZUMAB DERUXTECAN Cause?
Death (384)
Off label use (258)
Nausea (251)
Myelosuppression (242)
Fatigue (186)
Malignant neoplasm progression (171)
Vomiting (140)
Diarrhoea (132)
Pneumonitis (125)
Metastases to central nervous system (103)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which TRASTUZUMAB DERUXTECAN Alternatives Have Lower Interstitial lung disease Risk?
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-DKST
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-DTTB
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB EMTANSINE
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-PKRB
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-QYYP